{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:36:53Z","timestamp":1791059813712,"version":"4.1.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>These recommendations provide guidance on the optimal timing for transitioning from intravenous to oral antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of transitioning to oral therapy versus continuing parenteral therapy of the total duration of treatment, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The guidelines panel suggests transitioning to oral antibiotics in patients with cUTI who are clinically improving, able to take medication, and for whom an effective oral option is available, rather than continuing parenteral therapy for the remaining treatment duration, regardless of the presence of associated Gram-negative bacteremia. An effective oral option needs to be active against the causative pathogen and achieve therapeutic levels in the urine and relevant tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Parenteral and oral antibiotics used to complete treatment courses for cUTI provide similar efficacy and adverse events, especially in the context of shorter duration of therapy. This recommendation places a high value on reducing avoidable intravenous catheter-related adverse events, costs, and resources, as well as taking into account practical aspects of antibiotic administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf461","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:05:37Z","timestamp":1765458337000},"page":"i68-i78","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections \u2013 Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-9099","authenticated-orcid":false,"given":"Barbara W","family":"Trautner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s W","family":"Cort\u00e9s-Penfield","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston VA Health Care System, Boston University School of Medicine , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Horstman","sequence":"additional","affiliation":[{"name":"Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Department of Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Moran","sequence":"additional","affiliation":[{"name":"Clinical Emergency Medicine, David Geffen School of Medicine at UCLA, Olive View-UCLA Medical Center , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colgan","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"O\u2019Horo","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Connolly","sequence":"additional","affiliation":[{"name":"Planned Parenthood of Orange and San Bernardino Counties , Orange, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Drekonja","sequence":"additional","affiliation":[{"name":"Infectious Disease Section, Minneapolis VA Health Care System, University of Minnesota Medical School , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-2623","authenticated-orcid":false,"given":"Larissa","family":"Grigoryan","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth B","family":"Lazenby","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Infectious Diseases, Medical University of South Carolina , Charleston, South Carolina ,","place":["USA"]},{"name":"Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina , Charleston, South Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Nicolle","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Manitoba School of Medicine , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1324-3517","authenticated-orcid":false,"given":"Anthony","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Department of Urology, Feinberg School of Medicine Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Yawetz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Lavergne","sequence":"additional","affiliation":[{"name":"Division of Medical Microbiology and Infection Control, Department of Pathology & Laboratory Medicine, Vancouver General Hospital, University of British Columbia , Vancouver, BC ,","place":["Canada"]},{"name":"Department of Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America (IDSA) , Arlington, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026082412171538400_ciaf461-B1","doi-asserted-by":"crossref","first-page":"ofac706","DOI":"10.1093\/ofid\/ofac706","article-title":"Can the future of ID escape the inertial dogma of its past? The exemplars of shorter is better and oral is the new IV","volume":"10","author":"Davar","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026082412171538400_ciaf461-B2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cmi.2023.04.009","article-title":"Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: are barriers real or simply perceived?","volume":"29","author":"Landersdorfer","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026082412171538400_ciaf461-B3","author":"AUGMENTIN (amoxicillin\/clavulanate potassium) FDA package insert","year":"2013"},{"key":"2026082412171538400_ciaf461-B4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jac\/dkx376","article-title":"Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis","volume":"73","author":"De Velde","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026082412171538400_ciaf461-B5","doi-asserted-by":"crossref","first-page":"ofae193","DOI":"10.1093\/ofid\/ofae193","article-title":"Real-world effectiveness of intravenous and oral antibiotic stepdown strategies for gram-negative complicated urinary tract infection with bacteremia","volume":"11","author":"Veillette","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026082412171538400_ciaf461-B6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/10600280221106789","article-title":"Use of fluoroquinolones or sulfamethoxazole-trimethoprim compared to beta-lactams for oral step-down therapy in hospitalized patients with uncomplicated enterobacterales bacteremia","volume":"57","author":"Mack","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2026082412171538400_ciaf461-B7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cmi.2022.10.004","article-title":"Highly versus less bioavailable oral antibiotics in the treatment of gram-negative bloodstream infections: a propensity-matched cohort analysis","volume":"29","author":"Mponponsuo","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026082412171538400_ciaf461-B8","doi-asserted-by":"crossref","first-page":"e2020166","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral \u03b2-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of enterobacterales bacteremia from a urine source","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026082412171538400_ciaf461-B9","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/ajhp\/zxac202","article-title":"Oral \u03b2-lactams vs fluoroquinolones and trimethoprim\/sulfamethoxazole for step-down therapy for Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae bacteremia","volume":"80","author":"McAlister","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"2026082412171538400_ciaf461-B10","doi-asserted-by":"crossref","first-page":"ofad657","DOI":"10.1093\/ofid\/ofad657","article-title":"Oral \u03b2-lactams, fluoroquinolones, or trimethoprim-sulfamethoxazole for definitive treatment of uncomplicated Escherichia coli or Klebsiella species bacteremia from a urinary tract source","volume":"11","author":"Alzaidi","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026082412171538400_ciaf461-B11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","article-title":"Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections","volume":"48","author":"Kutob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026082412171538400_ciaf461-B12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jgar.2019.07.026","article-title":"Oral antibiotics for the treatment of Gram-negative bloodstream infections: a retrospective comparison of three antibiotic classes","volume":"20","author":"Nisly","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026082412171538400_ciaf461-B13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijantimicag.2017.12.007","article-title":"Retrospective analysis comparing oral stepdown therapy for Enterobacteriaceae bloodstream infections: fluoroquinolones versus \u03b2-lactams","volume":"51","author":"Mercuro","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2026082412171538400_ciaf461-B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4065\/74.2.187","article-title":"The cephalosporins","volume":"74","author":"Marshall","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2026082412171538400_ciaf461-B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"key":"2026082412171538400_ciaf461-B16"},{"key":"2026082412171538400_ciaf461-B17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/ijms.80621","article-title":"Comparative-effectiveness of oral beta-lactams and fluoroquinolones for stepdown therapy in patients with enterobacterales bloodstream infections: a retrospective cohort study","volume":"20","author":"Bjork","year":"2023","journal-title":"Int J Med Sci"},{"key":"2026082412171538400_ciaf461-B18","doi-asserted-by":"crossref","first-page":"106560","DOI":"10.1016\/j.ijantimicag.2022.106560","article-title":"Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents","volume":"59","author":"Fosse","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026082412171538400_ciaf461-B19"},{"key":"2026082412171538400_ciaf461-B20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00467-008-0996-6","article-title":"Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children","volume":"24","author":"M\u00e5rild","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"2026082412171538400_ciaf461-B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/003655401750173922","article-title":"Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime","volume":"33","author":"Cronberg","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2026082412171538400_ciaf461-B22","author":"CEFTIN (cefuroxime axetil) FDA package insert","year":"2015"},{"key":"2026082412171538400_ciaf461-B23","doi-asserted-by":"crossref","first-page":"e0274194","DOI":"10.1371\/journal.pone.0274194","article-title":"A retrospective review of oral cephalosporins versus fluoroquinolones for the treatment of pyelonephritis","volume":"17","author":"Lin","year":"2022","journal-title":"PLoS One"},{"key":"2026082412171538400_ciaf461-B24","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1017\/ash.2023.435","article-title":"Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection","volume":"3","author":"Geyer","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026082412171538400_ciaf461-B25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1186\/s12879-020-05498-2","article-title":"Oral beta-lactam step down in bacteremic E. coli urinary tract infections","volume":"20","author":"Saad","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026082412171538400_ciaf461-B26","author":"CIPRO (ciprofloxacin hydrochloride) FDA package insert","year":"2016"},{"key":"2026082412171538400_ciaf461-B27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2026082412171538400_ciaf461-B28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2026082412171538400_ciaf461-B29","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","article-title":"Levofloxacin: a review of its use in the treatment of bacterial infections in the United States","volume":"63","author":"Croom","year":"2003","journal-title":"Drugs"},{"key":"2026082412171538400_ciaf461-B30","doi-asserted-by":"crossref","first-page":"e01989-17","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082412171538400_ciaf461-B31","author":"BACTRIM (sulfamethoxazole and trimethoprim double strength tablets) FDA package insert","year":"2013"},{"key":"2026082412171538400_ciaf461-B32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jiac.2017.05.005","article-title":"A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli: a pilot study","volume":"23","author":"Malaisri","year":"2017","journal-title":"J Infect Chemother"},{"key":"2026082412171538400_ciaf461-B33","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400 mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"key":"2026082412171538400_ciaf461-B34","first-page":"112","article-title":"Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy","volume":"78","author":"Concia","year":"2006","journal-title":"Arch Ital Urol Androl"},{"key":"2026082412171538400_ciaf461-B35","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cts.13665","article-title":"A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: a pilot study","volume":"16","author":"So-Ngern","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026082412171538400_ciaf461-B36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/IDR.S178183","article-title":"Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial","volume":"12","author":"Lojanapiwat","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2026082412171538400_ciaf461-B37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciab934","article-title":"Fosfomycin vs ciprofloxacin as oral step-down treatment for Escherichia coli febrile urinary tract infections in women: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"75","author":"Ten Doesschate","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026082412171538400_ciaf461-B38","doi-asserted-by":"crossref","first-page":"e0167723","DOI":"10.1128\/mbio.01677-23","article-title":"Daily fosfomycin versus levofloxacin for complicated urinary tract infections","volume":"14","author":"Rouphael","year":"2023","journal-title":"mBio"},{"key":"2026082412171538400_ciaf461-B39","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/jac\/dkad147","article-title":"Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial","volume":"78","author":"Sojo-Dorado","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026082412171538400_ciaf461-B40","first-page":"CD003237","article-title":"Modes of administration of antibiotics for symptomatic severe urinary tract infections","volume":"2007","author":"Pohl","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026082412171538400_ciaf461-B41","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1185\/03007990802550679","article-title":"Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials","volume":"24","author":"Vouloumanou","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026082412171538400_ciaf461-B42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026082412171538400_ciaf461-B43","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"2026082412171538400_ciaf461-B44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026082412171538400_ciaf461-B45","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.eclinm.2022.101750","article-title":"Duration of antibiotic treatment for Gram-negative bacteremia\u2014systematic review and individual participant data (IPD) meta-analysis","volume":"55","author":"Turjeman","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026082412171538400_ciaf461-B46","first-page":"1065","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","author":"BALANCE Investigators, for the Canadian Critical Care Trials Group","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082412171538400_ciaf461-B47","doi-asserted-by":"crossref","first-page":"e0078023","DOI":"10.1128\/aac.00780-23","article-title":"Safety of early oral ambulatory treatment of adult patients with bloodstream infections discharged from the emergency department","volume":"67","author":"Casado","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082412171538400_ciaf461-B48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000074526","article-title":"Penetration of antimicrobial agents into the prostate","volume":"49","author":"Charalabopoulos","year":"2003","journal-title":"Chemotherapy"},{"key":"2026082412171538400_ciaf461-B49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0090-4295(02)02300-2","article-title":"Antimicrobial therapy for bacterial and nonbacterial prostatitis","volume":"60","author":"Fowler","year":"2002","journal-title":"Urology"},{"key":"2026082412171538400_ciaf461-B50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-5347(17)61919-0","article-title":"Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid","volume":"103","author":"Stamey","year":"1970","journal-title":"J Urol"},{"key":"2026082412171538400_ciaf461-B51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/idr14040067","article-title":"Oral fosfomycin formulation in bacterial prostatitis: new role for an old molecule-brief literature review and clinical considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect Dis Rep"},{"key":"2026082412171538400_ciaf461-B52","doi-asserted-by":"crossref","first-page":"ofab620","DOI":"10.1093\/ofid\/ofab620","article-title":"Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: a multicenter, retrospective cohort study","volume":"9","author":"Wald-Dickler","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026082412171538400_ciaf461-B53","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026082412171538400_ciaf461-B54","doi-asserted-by":"crossref","first-page":"ofz364","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. \u00df-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026082412171538400_ciaf461-B55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026082412171538400_ciaf461-B56","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/AAC.01638-15","article-title":"Two simple rules for improving the accuracy of empiric treatment of multidrug-resistant urinary tract infections","volume":"59","author":"Linsenmeyer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082412171538400_ciaf461-B57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jama.2012.80","article-title":"Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial","volume":"307","author":"Hooton","year":"2012","journal-title":"JAMA"},{"key":"2026082412171538400_ciaf461-B58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1995.03520250057034","article-title":"Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women","volume":"273","author":"Hooton","year":"1995","journal-title":"JAMA"},{"key":"2026082412171538400_ciaf461-B59","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciad009","article-title":"Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated bacteremia","volume":"76","author":"McAteer","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026082412171538400_ciaf461-B60","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s12913-018-3751-0","article-title":"Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department","volume":"18","author":"Almarzoky Abuhussain","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2026082412171538400_ciaf461-B61","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0020-1383(11)70129-2","article-title":"Patients\u2019 views and experience of intravenous and oral antimicrobial therapy: room for change","volume":"42 Suppl 5","author":"Bamford","year":"2011","journal-title":"Injury"},{"key":"2026082412171538400_ciaf461-B62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.idh.2018.05.002","article-title":"A survey of reported behaviours, attitudes and knowledge related to antibiotic use of hospitalised patients in Thailand","volume":"23","author":"Sutthiruk","year":"2018","journal-title":"Infect Dis Health"},{"key":"2026082412171538400_ciaf461-B63","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1017\/ice.2021.22","article-title":"Cost minimization analysis of outpatient parenteral\/oral antibiotic therapy at a trauma hospital: public health system","volume":"42","author":"Loesch","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026082412171538400_ciaf461-B64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1542\/hpeds.2018-0193","article-title":"Economic burden of home antimicrobial therapy: OPAT versus oral therapy","volume":"9","author":"Krah","year":"2019","journal-title":"Hosp Pediatr"},{"key":"2026082412171538400_ciaf461-B65","doi-asserted-by":"crossref","first-page":"e2582","DOI":"10.1093\/cid\/ciaa985","article-title":"Clinical experience of implementing oral versus intravenous antibiotics (OVIVA) in a specialist orthopedic hospital","volume":"73","author":"Azamgarhi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026082412171538400_ciaf461-B66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciad119","article-title":"Real-world application of oral therapy for infective endocarditis: a multicenter, retrospective, cohort study","volume":"77","author":"Freling","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf461\/66031114\/ciaf461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i68\/66031114\/ciaf461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i68\/66031114\/ciaf461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:17:30Z","timestamp":1787588250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/Supplement_3\/i68\/8384096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":66,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,12,19]]},"published-print":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf461","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,12,19]]}}}